Efficacy and safety of aclidinium/formoterol versus monotherapies and aclidinium versus placebo in Chinese and other Asian patients with moderate-to-severe COPD: The AVANT Phase 3 study

AVANT was a Phase 3, 24-week, randomized, parallel-group, double-blind, double-dummy, placebo-controlled study to assess the efficacy and safety of aclidinium/formoterol 400 μg/12 μg combination vs monotherapies and aclidinium vs placebo (1:1:1:1) in Asian patients (∼70% of whom were Chinese) with m...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Respiratory medicine 2023-11, Vol.218, p.107393-107393, Article 107393
Hauptverfasser:	Sun, Yongchang, Molins, Eduard, Daoud, Sami Z., Trivedi, Roopa, Stewart, Catherine, Lamarca, Rosa, Bharali, Pranob, Garcia-Gil, Esther
Format:	Artikel
Sprache:	eng
Schlagworte:	Asia Bronchodilation Chronic obstructive pulmonary disease Long-acting muscarinic antagonist Long-acting β2-agonist
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!